Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX2004 in Advanced Tumors
NCT07110584Phase 2Recruiting
- Sponsor
- ModeX Therapeutics
- Start
- Oct 2025
- Primary completion
- Jun 2031
- Modality
- T-cell Engagers, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of MDX2004 in advanced cancer, sponsored by ModeX Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
MDX2004
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT07110584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110584.